Reticular offers AI‑driven genetic screening tools that generate interpretable risk assessments for multiple hereditary conditions across an individual’s family history. The platform integrates genomic data with clinical information to provide a comprehensive health picture, enabling clinicians and consumers to make informed preventive or treatment decisions. Revenue is generated through subscription‑based access to the analytics suite and per‑test licensing for healthcare providers.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biological AI models face challenges in precise control over protein properties due to data scarcity, hindering reliable protein design and generation. This limitation impacts the efficiency and effectiveness of therapeutic protein development and RNA therapeutics.
Solution
Reticular develops mechanistic interpretability techniques tailored for biological AI models, enabling precise steering and control of these models even with limited validation data. By peering inside biological AI, Reticular facilitates understanding of its decision-making processes. This approach accelerates development by reducing the need for extensive real-world testing and allows building safeguards directly into model capabilities. Reticular's technology enhances the reliability of protein design and generation, making it easier to steer models reliably.
Target Audience
Reticular targets startups working with biological language models (especially in protein engineering), research teams exploring mechanistic interpretability, and pharma teams building generative pipelines for antibodies and protein therapeutics.
Features
- Mechanistic interpretability techniques for biological sequence models
- Semantic biological interpretability using DNA & protein annotation databases
- Sample-efficient guidance algorithms for protein engineering
- Ability to understand the decision-making of biological AI
- Steering models reliably with limited validation data
- Accelerating development by reducing real-world testing
- Building safeguards directly into model capabilities